Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
Company (NYSE:ALC) faced public shareholder resistance after Yunqi Capital, a 5.1% shareholder, sent a letter urging STAAR Surgical’s board to terminate the proposed merger announced Aug 5, 2025.
Yunqi cited a postponed special meeting now set for December 3, 2025, reported vote results showing roughly 72% of outstanding shares opposed the merger and about 81% opposed a $55 million executive compensation package, and said Alcon provided no commitment to increase consideration as of October 24, 2025.
STAAR Surgical (merger with Alcon, ALC) postponed its Special Meeting of Stockholders from November 6, 2025 to December 3, 2025 at 8:30 a.m. PT because of ongoing discussions with Alcon. The new record date for voting eligibility is the close of business on October 24, 2025. Stockholders holding shares as of that record date will be eligible to vote at the postponed meeting, and STAAR will provide a notice and meeting materials in advance. Stockholders with voting questions are instructed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at the provided toll-free and broker phone numbers.
Summary not available.
Summary not available.
Alcon (SIX/NYSE: ALC) and STAAR Surgical (NASDAQ: STAA) agreed to adjourn STAAR’s Special Meeting of Stockholders originally scheduled for October 23, 2025 in connection with STAAR’s merger agreement with Alcon. The Special Meeting is adjourned until 8:30 a.m. Pacific Time on November 6, 2025. No other business will be conducted at the Special Meeting. The record date for stockholders eligible to vote remains the close of business on September 12, 2025. Stockholders with voting questions are directed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at toll-free +1 877-750-8233 or banks/brokers +1 212-750-5833.
Summary not available.
Yunqi Capital (NASDAQ:STAA), a 5.1% STAAR shareholder, urged the board to hold the special shareholder meeting on October 23, 2025 and reiterated its opposition to the proposed sale to Alcon. Yunqi criticized STAAR’s pre-merger process and called recent company disclosures “disingenuous.”
Yunqi highlighted preliminary Q3 results: China revenue YTD $142.6M, estimated Q3 China revenue ≈$54.4M, $25.6M consignment revenue, and said Q3 sales exceeded consensus by 2.8%. Yunqi projects China sales of $180–200M for 2026 versus STAAR’s $160M guide and flagged missing margin/profit detail before the vote.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reported preliminary Q3 2025 net sales of $94.7 million, a 6.9% increase versus $88.6 million a year earlier. Results included $25.9 million recognized in Q3 from a December 2024 ICL shipment to a China distributor that received extended payment terms.
Excluding that collection, the company saw 7.7% growth outside China while China distributors reduced purchases, lowering nine-month sales as they trimmed inventory by approximately $80–$85 million. Figures are unaudited and subject to final 10-Q review. A special stockholder meeting on Oct 23, 2025 will vote on the Alcon merger proposal.
Broadwood Partners (NASDAQ: STAA), which holds 27.5% of STAAR outstanding shares, sent a letter to STAAR Surgical’s board on October 17, 2025 urging directors to allow a timely shareholder vote on the proposed sale to Alcon (NYSE: ALC). Broadwood urges shareholders to vote AGAINST the acquisition announced August 5, 2025, arguing the board pursued a poorly designed process and an inadequate price.
Broadwood warns the board against delaying the October 23, 2025 vote or issuing misleading statements, and says shareholders and proxy advisors oppose the deal; it calls for the board to accept the vote result and work with shareholders if the transaction is rejected.